Clinical trials
Observational Multiple Sclerosis trials in Turkey (Türkiye)
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
100 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 8 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 13 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 7 |
| 2025 | 16 |
| 2026 | 21 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 63 |
| Recruiting | 14 |
| Not yet recruiting | 9 |
| Unknown status | 8 |
| Enrolling by invitation | 5 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gazi University | 14 |
| Sanko University | 9 |
| Hacettepe University | 7 |
| Ankara Yildirim Beyazıt University | 5 |
| Istanbul University - Cerrahpasa | 5 |
| Kutahya Health Sciences University | 4 |
| Dokuz Eylul University | 3 |
| Kahramanmaras Sutcu Imam University | 3 |
| Marmara University | 3 |
| Selcuk University | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 100 |
| Fatigue | 17 |
| Multiple Sclerosis, Relapsing-Remitting | 6 |
| Sleep Initiation and Maintenance Disorders | 6 |
| Urinary Incontinence | 4 |
| Anxiety Disorders | 3 |
| Kinesiophobia | 3 |
| Sarcopenia | 3 |
| Stroke | 3 |
| Dysmenorrhea | 2 |
Trials
Showing 1 to 25 of 100. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.